Business Context and Reporting Period
Company: Arrowhead Research Corporation (Arrowhead)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Arrowhead is a nanomedicine company developing therapeutic products through majority-owned subsidiaries (Calando Pharmaceuticals, Ablaris Therapeutics) and minority investments (Nanotope, Leonardo Biosystems). The company focuses on cancer, obesity, and tissue regeneration. In January 2011, Arrowhead divested its interest in Unidym, Inc., which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2011 | Six Months Ended Mar 31, 2010 |
|---|---|---|
| Revenue | $296,139 | $0 |
| Net Income (Loss) Attributable to Arrowhead | $1,467,555 | $(3,398,887) |
| Operating Loss (Continuing Ops) | $(5,147,385) | $(2,715,625) |
| Income from Discontinued Operations | $5,361,713 | $(1,125,697) |
| Cash and Cash Equivalents (End of Period) | $4,789,599 | $2,593,044 |
| Total Assets | $15,236,725 | $12,354,542 |
| Total Liabilities | $3,014,650 | $4,276,246 |
| Stockholders' Equity | $12,222,075 | $8,078,296 |
Liquidity: Cash decreased by approximately $2.1 million during the six-month period, primarily due to operational spending. Management anticipates sufficient cash to fund operations for at least the next twelve months.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $1.47 million for the six months ended March 31, 2011, compared to a net loss of $3.4 million in the prior year period. This reversal is primarily driven by a $3.9 million gain on the sale of Unidym (discontinued operations) and non-cash gains from changes in derivative values ($869,422) and marketable securities ($359,920).
- Operating Expenses: Total operating expenses for continuing operations increased to $5.44 million (six months 2011) from $2.72 million (six months 2010). This increase was largely due to a $2.0 million licensing fee paid to the University of Texas for Ablaris Therapeutics and increased patent expenses ($370,000 vs. $37,000).
- Divestiture: The sale of Unidym in January 2011 removed a significant cash-burning operation from continuing operations, resulting in a gain on disposal of $3.9 million.
- Derivative Accounting: Significant non-cash gains were recorded due to the change in fair value of derivative liabilities (warrants and exchange rights), totaling approximately $881,000 in gains for the six-month period.
Guidance, Outlook, and Risks
Management Commentary:
- Strategy: The company is executing a cash conservation strategy, scaling back development efforts at subsidiaries, and seeking out-licensing opportunities or strategic partnerships.
- Liquidity Outlook: Management believes current cash ($4.8 million), proceeds from the sale of Wisepower stock (received for Unidym), and the ability to redeem warrants (potential $4.0 million) will fund operations for the next 12 months. However, further equity financing or asset sales will likely be necessary for long-term sustainability.
- Subsidiary Focus: Calando has closed its laboratory and shifted focus to licensing its RNAi technology. Ablaris was formed in Q1 2011 to pursue anti-obesity therapeutics.
Risks and Contingencies:
- NASDAQ Compliance: The company received a deficiency letter regarding the minimum bid price requirement ($1.00). It has a grace period until June 6, 2011, to regain compliance or risk delisting.
- Capital Needs: As a development-stage company with limited revenue, the company is dependent on raising additional capital. Failure to secure funding could force further curtailment of operations.
- Debt Obligations: Calando has a $500,000 convertible note maturing in November 2013. Failure to repay could lead to insolvency.
- Derivative Volatility: A significant portion of the reported income is non-cash and derived from the fair value changes of warrants and other derivatives, which are subject to market volatility.
Investor Verification Checklist
- Quality of Earnings: Verify the extent to which the reported net income is driven by non-cash items (derivative gains, gain on sale of Unidym) versus core operating revenue.
- Cash Burn Rate: Confirm the sustainability of the $4.8 million cash balance given the ongoing operational expenses of Calando and Ablaris.
- NASDAQ Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by June 6, 2011, to avoid delisting.
- Unidym Earn-outs: Review the terms of the Unidym sale to Wisepower, specifically the contingent payments (up to $140 million) and the marketability of the Wisepower stock received as consideration.
- Derivative Liabilities: Assess the risk of future losses if the company's stock price declines, which would increase the fair value of the derivative liabilities (warrants).